Document is current
Any future updates will be listed below
-
Authors
Car, Elif https://orcid.org/0000-0003-4356-4722
Vandenplas, Yannick https://orcid.org/0000-0002-6028-8486
Lacosta, Teresa Barcina https://orcid.org/0000-0002-6487-2479
Simoens, Steven https://orcid.org/0000-0002-9512-2005
Huys, Isabelle https://orcid.org/0000-0002-4738-8298
Vulto, Arnold G.
Barbier, Liese https://orcid.org/0000-0003-1786-2080
-
Funding
Funding for this research was provided by:
KU Leuven and the Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL) Fund.
- License Information
-
More Information
Article History
Accepted: 26 September 2024
First Online: 29 November 2024
Declarations
:
: SS, IH and AV are founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL Fund). AV is involved in consulting, advisory work and speaking engagements for a few companies, i.e., Accord, Amgen, Biogen, Effik, Medicines for Europe, Pfizer/Hospira, Mundipharma, Roche, Novartis, Sandoz. SS was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer and MSD; he has participated in advisory board meetings for Pfizer, Organon and Amgen; he has contributed to studies on biologics and biosimilars for Hospira, Celltrion, Mundipharma, Pfizer and Biogen; and he has had speaking engagements for Abbott, Amgen, Biogen, Celltrion and Sandoz. EC, YV, TBL, and LB have no conflicts of interest to declare. All authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.
: This work was supported by the KU Leuven and the Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL) Fund.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: EC: study implementation (title/abstract screening, full-text screening, data extraction, and data analysis), preparation of draft manuscript, review of draft manuscript, and interpretation of results. YV: study design, study implementation (title/abstract screening, full-text screening, and data extraction), review of draft manuscript, and interpretation of results. TBL: study implementation (title/abstract screening, full-text screening, and data extraction), review of draft manuscript, and interpretation of results. SS: review of draft manuscript and interpretation of results. IH: review of draft manuscript and interpretation of results. AGV: review of draft manuscript and interpretation of results. LB: study design, study implementation (title/abstract screening and full-text screening), review of draft manuscript, and interpretation of results. All authors have read and approved the final version of the manuscript.
